by nikki mann | Oct 11, 2021 | News
We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global pharmaceutical company headquartered in Japan, works across more than 70 countries in the US, Europe and Asia. They bring to the...
by nikki mann | Oct 6, 2021 | News
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful Business Support Organisation. The OBN Awards, now in their 13th year, celebrate individuals and life sciences companies that...
by nikki mann | Aug 4, 2021 | News
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein that plays a key role in transforming normal tissue to cancerous, as a possible target for drug development. The...
by nikki mann | Jul 1, 2021 | News
Namshik Han’s group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to work against COVID-19 – of which only 40 are currently being tested in COVID-19 clinical trials. In a study published this week in Science Advances,...
by nikki mann | Jun 2, 2021 | News
We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite and online community platform, as part of the new University Enterprise Zone (UEZ) initiative. The delivery team behind Connect: Health Tech is the Milner...
by nikki mann | May 24, 2021 | News
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid response data analysis pump prime call. This exciting new call was designed to seek collaborative project proposals from CRUK...
